help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prüfer, K.
Right arrow Articles by Barsony, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prüfer, K.
Right arrow Articles by Barsony, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*1,25-DIHYDROXYCHOLECALCIFEROL
Molecular Endocrinology 16 (5): 961-976
Copyright © 2002 by The Endocrine Society

Degradation of RXRs Influences Sensitivity of Rat Osteosarcoma Cells to the Antiproliferative Effects of Calcitriol

Kirsten Prüfer, Claudia Schröder, Krisztina Hegyi and Julia Barsony

Laboratory of Cell Biochemistry and Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Dr. Julia Barsony, Laboratory of Cell Biochemistry and Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 8 Center Drive, Room 422, Bethesda, Maryland 20892. E-mail: jul{at}helix.nih.gov.

Several cell lines, including ROS17/2.8 rat osteosarcoma (ROS) cells, contain functional VDRs and RXRs but are resistant to the antiproliferative effects of calcitriol and retinoids. We explored the role of receptor degradation in this hormone resistance. Results of transactivation assays indicated that ROS cells contain insufficient amounts of RXR to activate a DR-1 reporter, and Western blot analyses of cell extracts showed that the degradation of RXR is accelerated and produces an aberrant 45-kDa RXR. We stably expressed functional fluorescent chimeras of VDR and RXR [green fluorescent protein (GFP)-VDR; yellow fluorescent protein (YFP)-RXR] to evaluate degradation mechanisms and the impact of excess receptor expression on antiproliferative effects. Microscopy showed a diminished expression of YFP-RXR in ROS cells compared with the expression in CV-1 cells. Treatment with inhibitors of proteasomal degradation (lactacystin and MG132) selectively enhanced GFP-VDR and YFP-RXR expression and also increased the endogenous levels of VDR and RXR. Expression of GFP-VDR had no effect on the sensitivity of ROS cells to calcitriol. Increases of RXR levels by YFP-RXR expression, drug treatments, or the combination of the two, however, restored the growth-inhibitory effects of calcitriol and 9-cis-RA and restored p21 induction by calcitriol. These studies revealed that an accelerated and aberrant RXR degradation could cause resistance to the antiproliferative effects of calcitriol and retinoids in ROS cells.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
H.-J. Ting, B.-Y. Bao, J. E. Reeder, E. M. Messing, and Y.-F. Lee
Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1{alpha},25-Dihydroxyvitamin D3 Responsiveness
Mol. Cancer Res., September 1, 2007; 5(9): 967 - 980.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Narayanan, V. A. T. Sepulveda, M. Falzon, and N. L. Weigel
The Functional Consequences of Cross-talk between the Vitamin D Receptor and ERK Signaling Pathways Are Cell-specific
J. Biol. Chem., November 5, 2004; 279(45): 47298 - 47310.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Takiyama, N. Miyokawa, A. Sugawara, S. Kato, K. Ito, K. Sato, K. Oikawa, H. Kobayashi, S. Kimura, and M. Tateno
Decreased Expression of Retinoid X Receptor Isoforms in Human Thyroid Carcinomas
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5851 - 5861.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
F. CASAS, L. DAURY, S. GRANDEMANGE, M. BUSSON, P. SEYER, R. HATIER, A. CARAZO, G. CABELLO, and C. WRUTNIAK-CABELLO
Endocrine regulation of mitochondrial activity: involvement of truncated RXR{alpha} and c-Erb A{alpha}1 proteins
FASEB J, March 1, 2003; 17(3): 426 - 436.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
K. Prufer and J. Barsony
Retinoid X Receptor Dominates the Nuclear Import and Export of the Unliganded Vitamin D Receptor
Mol. Endocrinol., August 1, 2002; 16(8): 1738 - 1751.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society